Slide 1: Genetic Technologies Limited: Disease Risk Assessment on a Global Scale
For personal use only GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach
Slide 3: Revolutionising genetics
For personal use only Our patented tests are designed to predict an individual’s risk of developing chronic disease, Revolutionising empowering them to make informed decisions about their health. genetics. Our lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-heredi
Slide 4: Global healthcare spending and chronic disease
By 2020, 50 percent of Cancer global health care For personal use only Cardiovascular expenditures will be Respiratory Global healthcare spent on these diseases: spending is expected to reach $8.7 trillion by 2020. The number of diabetes sufferers globally is expected to rise from 415 million to Chr
Slide 5: Targeted screening reduces the cost of healthcare
For personal use only Targeted Early detection of disease reduces the need screening for expensive, late-stage care. reduces the Limited screening resources must be targeted to individuals who are at increased cost of risk of developing disease. healthcare.
Slide 6: BREVAGenplus predicts five-year breast cancer risk
For personal use only Our flagship test, BREVAGenplus®, predicts a woman’s risk of developing breast cancer in the next 5 years. Even with no family history. 7
Slide 7: BREVAGenplus targets screening, medication and lifestyle resources
More frequent Screening For personal use only mammograms MRIs BREVAGenplus® allows providers to target limited resources to Selective estrogen receptor modulators Medication (SERMs) women who are Aromatase inhibitors (Ais) most likely to develop breast cancer. Reduced alcohol Lifestyle consumption W
Slide 8: Colon Cancer – Early Diagnosis
Colon Cancer – Early Diagnosis For personal use only CRC is the 3rd leading cause of cancer-related deaths in the United States. Most mortality cases are preventable through early detection and the removal of precancerous polyps. Solving the Compliance Problem The main challenge with colon cancer sc
Slide 9: Additional screening tests are in development
Additional screening tests are in development. For personal use only An enhanced breast cancer test is undergoing final validation. Our colon cancer test will be available early in 2019. Additional tests will be introduced soon after. 4Q 2018 1Q 2019 2Q 2019 3Q 2019 4Q 2019 1Q 2020 10
Slide 10: Respected collaborators accelerate development
Respected collaborators accelerate development and validate clinical use of our tests. For personal use only The University of Melbourne is Australia’s peak research university. Our collaboration with Professor John Hopper led to our NHMRC Grant. The National Health and Medical Research Council is A
Slide 11: Most genetic tests are non-clinical
For personal use only Most genetic tests on the market are limited to non-clinical Consumers are willing to purchase genetic testing kits for genealogy, applications. paternity and nutrition. GTG is in a unique position to capitalize on this trend with first-to-market clinical applications. MIT Tech
Slide 12: Global Opportunity – US and Australia
Global Opportunity – US and Australia For personal use only • GTG operates a CLIA-approved laboratory, providing clinically actionable test results to the US market. • Through our US subsidiary Phenogen Sciences, more than 6,000 BREVAGenplus®, test kits have been sold into the clinical market over t
Slide 13: Global Opportunity - China
Global Opportunity - China For personal use only • GTG has been invited to enter the market in China through the Hainan Medical Pilot Zone. • Opportunity to deliver large-scale population health initiatives that will dramatically increase the effectiveness of existing screening and treatment program
Slide 14: Hainan Medical Pilot Zone
For personal use only • Part of the Hainan Free Trade Zone Initiative • Bring together best-in-class medical care, physicians, treatments, technology, conferences and cutting-edge medical product development via a mix of government institutions, and local and foreign companies • Allows foreign compa
Slide 15: Healthy China 2030
• Chinese Central Government’s comprehensive For personal use only healthcare plan for 1.5 billion people • Disease prevention is a means of controlling costs • Chinese government can enforce penalties for non-compliance with preventive healthcare protocols (i.e. travel or other personal restriction
Slide 16: Zishan Health Consultancy
Fast-track access to the Chinese Food and Drug Administration, an institution with For personal use only long product review and approval times Well-connected in the Chinese healthcare Zishan sector, including medical devices and diagnostics Health Consultancy Track record of successfully introducin
Slide 17: 2018: Aligning Structure with Strategy
Redirected funding to Refreshed board for an Transitioned from direct For personal use only R&D to develop a pipeline entrepreneurial focus and salesforce to an of additional tests for global expertise ecommerce platform chronic disease While these initiatives impacted our ability to generate Entere
Slide 18: Join the Community of GTG Shareholders
For personal use only We recognise that a critical element of our success is the continued support of our shareholders. We Join the appreciate their confidence in us during this period of intense R&D and realignment. Community of GTG To support our continued execution of these Shareholders initiativ
Slide 19: Thank You
Thank You For personal use only Paul Kasian Chairman and CEO Email: paul.kasian@gtglabs.com Web: www.gtgcorporate.com 20